Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1938 1
1939 1
1940 2
1943 1
1949 5
1950 4
1951 2
1952 1
1953 2
1954 5
1955 3
1956 1
1957 5
1958 3
1959 6
1960 5
1961 4
1962 5
1963 6
1964 4
1965 4
1966 4
1967 4
1968 9
1969 5
1970 5
1971 5
1972 3
1973 2
1974 10
1975 6
1976 14
1977 10
1978 13
1979 11
1980 10
1981 11
1982 15
1983 21
1984 13
1985 18
1986 15
1987 16
1988 13
1989 29
1990 29
1991 20
1992 28
1993 22
1994 30
1995 24
1996 30
1997 22
1998 30
1999 34
2000 31
2001 25
2002 43
2003 41
2004 35
2005 33
2006 51
2007 56
2008 63
2009 62
2010 67
2011 80
2012 103
2013 86
2014 95
2015 95
2016 101
2017 89
2018 89
2019 100
2020 136
2021 137
2022 138
2023 147
2024 150
2025 156
2026 78

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,635 results

Results by year

Filters applied: . Clear all
Page 1
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Neelapu SS, et al. Among authors: munoz j. Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. Blood. 2023. PMID: 36821768 Free PMC article.
Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity.
Marin I, Boix O, Garcia-Garijo A, Sirois I, Caballe A, Zarzuela E, Ruano I, Attolini CS, Prats N, López-Domínguez JA, Kovatcheva M, Garralda E, Muñoz J, Caron E, Abad M, Gros A, Pietrocola F, Serrano M. Marin I, et al. Among authors: munoz j. Cancer Discov. 2023 Feb 6;13(2):410-431. doi: 10.1158/2159-8290.CD-22-0523. Cancer Discov. 2023. PMID: 36302218 Free PMC article.
Current and future therapies for follicular lymphoma.
Zinzani PL, Muñoz J, Trotman J. Zinzani PL, et al. Among authors: munoz j. Exp Hematol Oncol. 2024 Aug 22;13(1):87. doi: 10.1186/s40164-024-00551-1. Exp Hematol Oncol. 2024. PMID: 39175100 Free PMC article. Review.
Polyamine-dependent metabolic shielding regulates alternative splicing.
Zabala-Letona A, Pujana-Vaquerizo M, Martinez-Laosa B, Ponce-Rodriguez M, Garcia-Longarte S, Mendizabal I, Gimeno A, Rogalska M, Tan J, Cabrera D, van Liempd S, Ximenez-Embun P, Espinosa S, Fagoaga-Eugui M, Peccati F, Zakrzewski M, Astobiza I, Arana-Castañares M, Cherkaoui S, Sendino M, Martín-Barros I, Ercilla A, Bozal-Basterra L, Carlevaris O, Arruabarrena-Aristorena A, Pérez-Andrés E, Santamaría-Zamorano T, Ferrer-Bonsoms JA, Carazo F, Cieśla M, Lobato C, Seoane J, Martín-Martín N, Barrio R, Sutherland JD, Aransay AM, Falcón-Pérez JM, Martínez-Pastor B, Rubio A, Blanco FJ, Hogarty MD, Morscher RJ, Berra E, Serwa RA, Jiménez-Barbero J, Jiménez-Osés G, Efeyan A, Finley L, Lizcano JM, Muñoz J, Valcarcel J, Carracedo A. Zabala-Letona A, et al. Among authors: munoz j. Nature. 2026 Mar;651(8106):819-828. doi: 10.1038/s41586-025-09965-1. Epub 2026 Jan 14. Nature. 2026. PMID: 41535471 Free PMC article.
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
Brooks TR, Zabor EC, Bedelu YB, Yang X, Karimi YH, Nedved AN, Wang Y, Dave N, Landsburg DJ, Baron K, Hu B, Trotier DC, Pophali PA, Miller J, Grover N, Reinert C, Major A, Schwarz T, Patel K, Salafian K, Ayers E, Sundaram S, Brody JD, McKenna M, Ryu Tiger YK, Sears-Smith M, Ghosh N, Peterson C, Khan C, Bliven SP, Narkhede M, Gibson A, Kline J, Munoz J, Garza-Morales R, Ho CI, Smith SD, Niu A, Hernandez-Ilizaliturri F, Chinyengetere F, Dave S, Abdel-Razeq N, Moustafa MA, Caimi PF, Hill BT. Brooks TR, et al. Among authors: munoz j. Blood. 2025 Oct 30;146(18):2177-2188. doi: 10.1182/blood.2025029117. Blood. 2025. PMID: 40663785
The lysosomal proteome of senescent cells contributes to the senescence secretome.
Rovira M, Sereda R, Pladevall-Morera D, Ramponi V, Marin I, Maus M, Madrigal-Matute J, Díaz A, García F, Muñoz J, Cuervo AM, Serrano M. Rovira M, et al. Among authors: munoz j. Aging Cell. 2022 Oct;21(10):e13707. doi: 10.1111/acel.13707. Epub 2022 Sep 10. Aging Cell. 2022. PMID: 36087066 Free PMC article.
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.
Chavez JC, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Wulff J, Williams CM, Winters J, Kloos I, Xu H, Neelapu SS. Chavez JC, et al. Among authors: munoz j. Blood. 2025 May 15;145(20):2303-2311. doi: 10.1182/blood.2024027347. Blood. 2025. PMID: 39938019 Free article. Clinical Trial.
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M. Jacobson CA, et al. Among authors: munoz j. Transplant Cell Ther. 2024 Jan;30(1):77.e1-77.e15. doi: 10.1016/j.jtct.2023.10.017. Epub 2023 Oct 27. Transplant Cell Ther. 2024. PMID: 37890589 Free article.
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.
Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO, Perales MA, Miklos DB, Fisher PW, Feng A, Navale L, Le Gall JB, Neelapu SS. Locke FL, et al. Among authors: munoz jl. J Clin Oncol. 2025 May 10;43(14):1695-1705. doi: 10.1200/JCO-24-01933. Epub 2025 Feb 13. J Clin Oncol. 2025. PMID: 39946666 Free PMC article. Clinical Trial.
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
Rosenthal A, Munoz J, Jun M, Wang T, Mutebi A, Wang A, Yang S, Osei-Bonsu K, Elliott B, Rivas Navarro F, Yu J, Brodkin S, Sacchi M, Ip A. Rosenthal A, et al. Among authors: munoz j. J Hematol Oncol. 2024 Aug 16;17(1):69. doi: 10.1186/s13045-024-01594-x. J Hematol Oncol. 2024. PMID: 39152509 Free PMC article.
2,635 results